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Edited by Sandro SonninoAbstract We investigate whether the fourth intracellular loop
(IL4) of D1 and D5 dopaminergic receptors (D1R, D5R) confers
D1-like subtype-speciﬁc signaling properties. Using chimeric
receptors (D1R-IL4B and D5R-IL4A), we show that swapping
of IL4 leads to a switch in dopamine aﬃnity and constitutive
activity of D1R and D5R. Dopamine potency was reduced for
both chimeras in comparison with wild-type receptors. More-
over, dopamine-mediated maximal activation was drastically
increased in cells expressing D1R-IL4B when compared with
those harboring D5R-IL4A or wild-type receptors. In conclusion,
IL4 plays a pivotal role in imparting subtype-speciﬁc ligand
binding and activation properties to highly homologous seven-
transmembrane receptors.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Dopamine (DA) mediates a variety of physiological eﬀects
through the activation of seven-transmembrane proteins be-
longing to the superfamily of G protein-coupled receptors
(GPCRs). Five distinct genes encoding the DA receptors
have been isolated and classiﬁed into D1-like and D2-like
receptors based on their ability to activate or inhibit adenylyl
cyclase (AC) activity, respectively. In mammals, two genes
encoding D1-like dopaminergic receptors are known and
referred to as D1 and D5 subtypes (also called D1A and
D1B, respectively) [1]. Functionally, the D5 receptor (D5R)
diﬀerentiates itself from the D1 receptor (D1R) by a higher
constitutive activity (agonist-independent activity), increased
aﬃnity and potency for agonists, decreased aﬃnity for an-* Corresponding author. Address: Ottawa Health Research Institute,
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doi:10.1016/j.febslet.2004.09.059tagonists/inverse agonists, and a lower agonist-mediated
maximal activation [2].
The cytoplasmic tail (CT) plays a crucial role in conferring
the subtype-speciﬁc DA binding aﬃnities and G protein
coupling properties displayed by the D1-like receptors [3,4].
However, the precise CT structural determinants imparting
speciﬁc functional signatures to the D1-like receptors remain
to be identiﬁed. Recently, we have observed that the D1R
truncated at Cys351, and thus harboring only the N-terminal
segment of the CT, displayed an increased DA aﬃnity and
constitutive activity suggesting a key role of this CT region in
regulating the equilibrium between the inactive and active
states of D1R [5]. Interestingly, Cys351 of D1R belongs to a
group of conserved Cys residues of CT shown to undergo
palmitoylation [6]. As Cys palmitoylation may anchor the CT
to the membrane, the encompassed N-terminal segment of
CT has been proposed to form a fourth intracellular loop
(IL4) and implicated in the proper G protein coupling of
rhodopsin and b2-adrenergic receptors (b2-AR) [7–10].
Moreover, its unique a-helical conformation, deduced from a
crystal structure of rhodopsin, has been postulated to govern
the formation of IL4 [11]. As a result, the IL4 segment has
been referred to as cytoplasmic a-helix 8 region (H8), whose
involvement in GPCR function is gaining increasing support
[12–15]. To date, the contribution of the putative IL4 to the
function of D1-like dopaminergic receptors has not been
explored. Most importantly, the primary structure of D1R
and D5R extending from the seventh transmembrane region
to two conserved Cys residues displays striking diﬀerences
that may underlie CT-conferred D1-like receptor-speciﬁc
functional features [3].
The main focus of the present paper is to investigate the
potential role of IL4 in the CT-conferred ligand binding and G
protein coupling properties of the D1-like receptors [3,4]. Our
results strongly suggest that IL4 is a major structural deter-
minant underlying the CT-conferred D1-like subtype-speciﬁc
functional signatures.2. Materials and methods
2.1. Drugs
N-[methyl-3H]-SCH23390 (82 Ci/mmol), [3H]-adenine (27 Ci/mmol),
and [14C]-cAMP (252 mCi/mmol) were from Amersham Pharmacia
Biotech (Baie d’Urfe, Quebec, Canada). DA, cis-ﬂupentixol (+)-buta-
clamol, SCH23390 (SCH) and 1-methyl-3-isobutylxanthine were from
Sigma/Research Biochemicals International (Oakville, Ontario, Can-
ada).blished by Elsevier B.V. All rights reserved.
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To construct the IL4 chimeric receptors (Fig. 1), we took advantage
of existing chimeras (D1R-CTB and D5R-CTA) in which the entire CT
was swapped between the human D1R and D5R [3]. In these newly
generated chimeras, all residues downstream of the second Cys of CT
(Cys351 in D1 and Cys379 in D5) were restored to wild-type primary
structure, leaving only IL4 in a mutated form (Fig. 1). In case of the
chimeric D1R-IL4B receptor, the CT of D5R was terminated at
Cys379, followed by D1R residues to complete the CT. In case of the
D5R-IL4A chimera, the CT of the D1R was terminated at Cys351,
followed by D5R residues for completion of the CT. The swap of the
IL4 between the D1R and D5R was achieved by gene splicing using a
PCR-based overlap extension method [16]. With respect to the D1R-
IL4B chimera, the ﬁrst round of PCR generated two fragments: the
ﬁrst fragment encoding the C-terminal portion of third intracellular
loop, transmembrane region 6, third extracellular loop and trans-
membrane region 7 (TM7) of D1R and IL4 of D5R (using the D1R-
CTB chimera as template), and the second fragment coding for CT
residues of D1R located downstream of IL4 (using the D5R-CTA
chimera as template). The ﬁrst fragment was ampliﬁed using primers
50-CACCACAGGTAATGGAAA-30 (forward primer) and 50-
GCAGAAGTGGCTGCACCCCAG-30 (reverse primer). The second
fragment was ampliﬁed using primers 50-TGCAGCCACTTCTGCCC-
TGCGACGAATAAT-30 (forward primer) and 50-TGCAACTTA-
ATTTTATTA-30 (reverse primer). Likewise, with respect to the
construction of D5R-IL4A chimera, the ﬁrst round of PCR generated
two fragments: the ﬁrst coding the N-terminus of the D5R up to IL4 of
D1R (using the D5R-CTA chimera as template) and the second
fragment coding the CT residues of the D5R located downstream of
Cys379 (using the D1R-CTB chimera as template). The ﬁrst fragment
was ampliﬁed using primers 50-TACGGTGGGAGG-30 (forward
primer) and 50-GCAAAGTCTGTAGCATCCTAAGAGGGT-30 (re-
verse primer). The second fragment was ampliﬁed using primers
50-TGCTACAGACTTTGCTCCCGCACGCCGGTG-30 (forward pri-
mer) and 50-TGCAACTTAATTTTATTA-30 (reverse primer). To fa-
cilitate the construction and identiﬁcation of the chimeric receptors, a
silent mutation was introduced in each construct to create a unique
restriction endonuclease site. For D1R-IL4B chimera, a MluI site wasFig. 1. Primary structure of the putative fourth intracellular loop (IL4)
of the human D1-like subtypes and schematic representation of wild-
type and chimeric receptors. (A) Alignment of the primary structure of
transmembrane region 7 (TM7) and IL4 between human D1R and
D5R. Identical residues found between the two primary structures are
indicated with an asterisk. The TM7 and IL4 are delimited by black
and white rectangles. (B) Putative topology of the wild-type D1R (open
circles) and D5R (ﬁlled circles), D1R-IL4B and D5R-IL4B chimeras is
depicted.introduced at nucleotide sequence corresponding to amino acid
residues 331 and 332 near the 30 end of TM7 of D1R, immediately up-
stream of the IL4 sequence of D5R (50-TATGCC-30 ! 50-TACGCG-
30: modiﬁed nucleotides are bold and underlined). For D5R-IL4A
chimera, a HindIII restriction site was introduced at nucleotide se-
quence corresponding to residues 367 and 368 located 30 of the
junction between the TM7 of D5R and IL4 sequence of D1R (50-
AAGGCA-30 ! 50-AAAGCT-30: modiﬁed nucleotides are bold and
underlined). Ampliﬁed fragments were separated on a 1% agarose gel
and appropriate bands were excised and puriﬁed by QIAEX II gel
extraction method (Qiagen, Valencia, CA). Diluted aliquots of the
paired fragments were combined and subjected to overlap PCR using
appropriate 50 and 30 ﬂanking primers. The resulting PCR products
were introduced into the expression vector pCMV5. The D1R-IL4B
fragment was subcloned into D1R-CTB/pCMV5 expression construct
using restriction enzymes MluI and XbaI. The D5R-IL4A fragment
(HindIII) was subcloned into linearized pCMV5 (KpnI–HindIII) to-
gether with the N-terminal portion of D5R-CTA (KpnI–HindIII) in a
3-piece ligation process. The nucleotide sequence of PCR products and
cloning sites was conﬁrmed by dideoxy sequencing using Sequenase
version 2.0 from Amersham Pharmacia Biotech (Baie d’Urfe, Quebec,
Canada).2.3. Cell culture and transfection
Human embryonic kidney 293 (HEK293) cells (American Type
Culture Collection, Manassas, VA, USA) were cultured at 37 C and
5% CO2 in minimal essential medium (MEM) supplemented with 10%
heat-inactivated fetal bovine serum (FBS) and gentamicin (10 lg/ml)
(Invitrogen, Burlington, Ontario, Canada). A modiﬁed calcium phos-
phate-mediated transfection of cells (2.5 106 cells/dish) was carried
out as described [17]. Brieﬂy, 100 ll of 2.5 M CaCl2 was added to a
plastic tube containing 10 lg of DNA in 900 ll of sterile milli-Q-water
and mixed. Then, 1 ml of 2· HEPES-buﬀered saline (HBS), pH 7.1
(0.28 M NaCl, 0.05 M HEPES, pH 7.0, and 1.5 mM Na3PO4, pH 7.1),
was added dropwise to the DNA-calcium solution, gently mixed by
ﬂicking the tube and used to transfect two 100-mm dishes at a time (5
lg/dish). Typically, 1 ml of transfection mixture was added dropwise to
a 100 mm-dish of cells containing 10 ml of complete MEM. When less
than 5 lg receptor DNA per dish was used in transfections, empty
pCMV5 vector was added to normalize the total amount of DNA.
Cells were incubated with the DNA-calcium phosphate precipitate
overnight prior to reseeding. All experiments were performed with cells
from 38 to 52 passages.2.4. Membrane preparation
Transfected HEK293 cells were washed with phosphate-buﬀered
saline (PBS), trypsinized, reseeded in 150-mm dishes and grown for an
additional 48 h. Crude membrane preparations expressing wild-type or
chimeric receptors were prepared as previously described [18]. Mem-
brane preparations were either used immediately (saturation studies)
or frozen in liquid nitrogen and stored at )80 C until needed (com-
petition studies).
2.5. Receptor binding assays
Membranes were resuspended in binding buﬀer (ﬁnal concentrations
in the binding assay: 50 mM Tris–HCl, pH 7.4, 120 mM NaCl, 5 mM
KCl, 4 mM MgCl2, 1.5 mM CaCl2, and 1 mM EDTA) using a
Brinkmann Polytron. Binding assays were carried out with 100 ll of
membranes in a total volume of 500 ll using [3H]-SCH23390 as ra-
dioligand. Saturation studies were performed with fresh membranes
and increasing concentrations of [3H]-SCH23390 (0.01–6 nM). Non-
speciﬁc binding was determined by the addition of 10 lM cis-ﬂupen-
tixol (dissolved in milli-Q-water). Competition studies were done using
frozen membranes thawed on ice. Membrane preparations were in-
cubated with a ﬁxed concentration of [3H]-SCH23390 (0.6 nM) and
increasing concentrations of competing ligand. Competition studies
using DA were done in the presence of 0.1 mM ascorbic acid (dissolved
in milli-Q-water). Membranes were incubated for 90 min at room
temperature and binding assays stopped using rapid ﬁltration through
glass ﬁber ﬁlters (GF/C, Whatman) as described before [18]. Radio-
activity bound to ﬁlters was measured using liquid scintillation
counting (Beckman Counter, LS 6500). Protein concentration was
assessed using the Bio-Rad assay kit with bovine serum albumin as
standard.
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Transfected HEK293 cells were reseeded in 6- or 12-well dishes and
whole cell cAMP assays performed in the presence of 1-methyl-3-
isobutylxanthine to assess the regulation of AC activity by wild-type
and chimeric receptors as described previously [2,18]. Intracellular
[3H]-cAMP was puriﬁed by sequential chromatography using Dowex
(AG 50W-X4) and alumina columns as described previously [19]. The
amount of intracellular [3H]-cAMP (CA) over the total amount of
intracellular [3H]-adenine (TU) was computed to determine the relative
AC activity (CA/TU1000). The maximal binding capacity (Bmax)
values were determined using a saturating concentration of [3H]-
SCH23390 (6 nM).
2.7. Statistics
Saturation and competition binding isotherms were analyzed using
the non-linear curve-ﬁtting program LIGAND to determine the
equilibrium dissociation constant or Kd (expressed as the reciprocal
transformation of aﬃnity constants) and Bmax values [20]. A simulta-
neous ﬁtting of dose-response curves was performed with ALLFIT [21]
using unconstrained and constrained (shared) parameters (bottom or
basal activity, top or maximal stimulation, eﬀective concentration that
elicits 50% of maximal response or EC50, slope factor). This was done
to establish whether diﬀerences observed between best-ﬁtted values
were statistically diﬀerent, i.e., whether constraining a speciﬁc curve
parameter to share a common value worsens the goodness of ﬁt. Kd
values are reported using the geometric mean standard error (S.E.).
The S.E. of geometric means were computed using the value of geo-
metric average multiplied by the S.E. of the averaged logarithmic
transform [22]. All other data are expressed as arithmetic means S.E.
unless stated otherwise. Homogeneity of variances was determined
using Fmax or Bartlett tests prior to statistical analyses [23]. One sample
t-test and analysis of variance (one-way ANOVA) with Newman–
Keuls multiple comparison test were performed using GraphPad Prism
version 4.0 for Windows, GraphPad Software, San Diego, CA, USA,
www.graphpad.com. The level of signiﬁcance was established at
P < 0:05.Table 1
Dissociation constants (Kd) and maximal binding capacity (Bmax)
values of N-[methyl-3H]-SCH23390 for wild-type and chimeric D1-like
receptors
Receptor Kd (nM) Bmax (pmol/mg prot.)
D1R 0.44 0.02 11.8 2.4
(0.35–0.55) (100)
D5R 0.81 0.02 16.8 2.1
(0.70–0.94) (160 20)
D1R-IL4B 0.14 0.01 ;# 0.59 0.14 ;#
(0.09–0.24) (5.0 0.7)
D5R-IL4A 0.64 0.03 ;w 16.0 1.0w
(0.49–0.83) (166 32)
Kd and Bmax values are expressed as geometric and arithmetic means
 S.E., respectively. Bmax values are also expressed as percent of D1R.
Lower and upper 95% of conﬁdence intervals of geometric means are
shown in brackets. Means are from six experiments done in duplicate
determinations.
w P < 0:05 when compared with D1R-IL4B.
# P < 0:05 when compared with D5R.
* P < 0:05 when compared with D1R.3. Results
3.1. IL4 modulates ligand binding properties and receptor
expression of D1-like subtypes
Our results suggest that substitution of IL4 does not impair
the ability of the chimeric receptors (Fig. 1) to bind with high
aﬃnity the benzazepine SCH23390 (Table 1), a selective D1-
like ligand behaving as a partial agonist in heterologous cells
[2,24]. Binding aﬃnities of SCH23390 at both chimeras were
signiﬁcantly increased in comparison with their respective pa-
rental receptors while retaining the wild-type pharmacological
proﬁle, i.e., a lower SCH23390 aﬃnity constant for the D5R
(Table 1). A similar trend was observed with competition
studies (Table 2).
Upon the reciprocal exchange of the IL4 region, the D1R-
IL4B chimera displayed an increased aﬃnity for DA that was
reminiscent of the aﬃnity for wild-type D5R. On the other
hand, the D5R-IL4B chimera displayed a partially reduced
DA aﬃnity in comparison with the wild-type D5R (Table 2).
The exchange of the IL4 segment between D1R and D5R did
not switch the subtype-speciﬁc inverse agonist aﬃnities (Table
2). Although slightly increased, the aﬃnities of both chimeras
for cis-ﬂupentixol were not statistically diﬀerent from their
respective parent receptors. Similar trend was also observed
with ((+)-butaclamol) aﬃnity, where the increase in aﬃnity
was greater and statistically signiﬁcant for both chimeras
compared with their respective parent receptors.
Moreover, our saturation studies revealed a drastic de-
crease (20- to 30-fold) in the Bmax of [3H]-SCH23390 in
cells expressing D1R-IL4B (Table 1). In contrast, the Bmax of[3H]-SCH23390 in cells expressing D5R-IL4A chimera re-
mained unchanged in comparison with its wild-type D5R
counterpart.
3.2. IL4 underlies the CT-conferred constitutive activity
phenotype of D1-like receptors
The role of IL4 in CT-conferred D1-like subtype-speciﬁc
agonist-independent and dependent activation of ACproperties
was assessed in intact transfected HEK293 cells under low and
high receptor expression. Using cells expressing low and com-
parable receptor levels (1–2 pmol/mg protein), dose- response
curves were performed to determine DA potency. Additional
inferences regarding the basal and maximal activation of AC
under the low receptor expression condition were drawn from
ALLFIT best-ﬁtted values using unconstrained and con-
strained simultaneous curve ﬁtting (Fig. 2A and E). In contrast,
the high receptor expression condition (maximum) was
achieved following a transfection with 5 lg DNA to evaluate
basal activity and DA-mediated maximal activation of AC was
measured under the high expression condition (Fig. 2C and D).
The D5R displayed higher agonist-independent activity in
comparison with the D1R (Fig. 2B and C) as reported previ-
ously [2,3,25]. Substitution of the variant IL4 residues pro-
duced a decrease of the agonist-independent activation of
D5R-IL4A chimera in comparison with the wild-type D5R
and beyond the levels measured for the D1R (Fig. 2B and C).
Furthermore, under comparable low but not high Bmax values,
we have shown that D1R-IL4B exhibited a signiﬁcant increase
in constitutive activity when compared with the wild-type D1R
(Fig. 2B and C). These ﬁndings are consistent with the lower
Bmax value of D1R-IL4B obtained under conditions leading to
high receptor expression and the linear relationship existing
between receptor density and constitutive activity. Impor-
tantly, the constitutive activity of D1R-IL4B chimera was in-
distinguishable from the wild-type D5R when assessed at a
similar low receptor expression (Fig. 2B and C).
3.3. IL4 modulates dopamine-mediated activation of AC by
D1-like receptors
We next examined the DA-mediated maximal stimulation of
AC in cells expressing comparable levels (low expression) of
wild-type and chimeric receptors using the best-ﬁtted maximal
Table 2
Dissociation constants (Kd) for binding of dopaminergic ligands to wild-type and chimeric D1-like receptors
Receptor SCH22390 (nM) Dopamine (nM) cis-Flupentixol (nM) (+)-Butaclamol (nM)
D1R 0.43 0.03 7953 422 2.51 0.32 3.97 0.29
(0.20–0.94) (4704–13447) (0.71–8.81) (1.91–8.23)
D5R 0.86 0.09 602 7 6.76 0.4 40.9 3.82
(0.30–2.43) (538–675) (3.78–12.1) (16.2–103)
D1R-IL4B 0.18 0.001 ;# 559 56 1.38 0.08# 1.56 0.08 ;#
(0.16–0.20) (207–1513) (0.76–2.52) (0.37–6.61)
D5R-IL4A 0.59 0.02w 2488 170 ;# ;w 5.11 0.29 ;w 23.8 0.85 ;# ;w
(0.45–0.76) (1265–4895) (2.94–8.88) (16.7–34.0)
Kd are expressed as geometric meansS.E. Means are from two to three experiments done in duplicate determinations. Lower and upper 95% of
conﬁdence intervals of geometric means are shown in brackets.
w P < 0:05 when compared with D1R-IL4B.
# P < 0:05 when compared with D5R.
* P < 0:05 when compared with D1R.
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by ALLFIT. As shown in Fig. 2B, DA-mediated maximal
stimulation of AC was signiﬁcantly greater in cells expressing
the D1R than those expressing the D5R. Interestingly, upon
exchange of the IL4 region, the D1R-IL4B chimera exhibited a
signiﬁcant increase in DA-mediated maximal activation of AC
when compared with the wild-type D1R (Fig. 2B). Conversely,
D5R-IL4A chimera displayed a signiﬁcant decrease of the DA-
mediated maximal activation of AC when compared with the
wild-type D5R (Fig. 2B). An investigation of DA-mediated
maximal stimulation of AC by the wild-type and chimeric D1-
like receptors under the maximal (high) expression condition
was carried out to assess further the role of IL4 in regulating
DA eﬃcacy. Statistically signiﬁcant diﬀerences in DA-medi-
ated maximal activation of AC were observed between low and
high expression conditions for wild-type receptors and D5R-
IL4A (Fig. 2D). Under the high expression condition, D1R-
IL4B chimera displayed a DA-mediated maximal activation of
AC akin to that of D5R and D5R-IL4A, despite an approxi-
mately 20-fold decrease in Bmax (Fig. 2D). These results sug-
gest that the coupling eﬃciency of D1R-IL4B to Gs/AC
pathways is signiﬁcantly increased in comparison with D1R,
D5R and D5R-IL4A.
The functional role of IL4 in the CT-induced changes in DA
potency (as indexed using EC50 values) was also tested. DA
potency was signiﬁcantly greater in HEK293 cells expressing
D5R than D1R (Fig. 2E and F) as previously reported [2,3,25].
Substitution of the variant IL4 residues produced a signiﬁcant
loss of DA potency for both receptors (Fig. 2E and F). More
speciﬁcally, in comparison with their respective parent recep-
tors, D1R-IL4B and D5R-IL4A displayed a signiﬁcant 2.5- and
19-fold decrease in DA potency, respectively (Fig. 2E and F).Fig. 2. DA-independent and dependent G protein coupling to AC activation o
(A) HEK293 cells were transfected with wild-type or chimeric D1-like recepto
0.02 lg of D5R, 5.0 lg of D1R-IL4B, and 0.02 lg of D5R-IL4A. The Bmax v
meanS.E.) were 2.8 0.3 (D1R), 2.6 0.4 (D5R), 0.6 0.1 (D1R-IL4B), a
single wells of a 12-well dish in the absence or presence of increasing concentr
log of DA concentrations. Each point is the arithmetic mean S.E. of four
cAMP formed (CA) over the total amount of [3H]-adenine uptake (TU) · 10
curve-ﬁtting using ALLFIT. Statistical signiﬁcance was determined using
constitutive activity (best-ﬁtted parameters for minimal response) and DA-m
response) of wild-type and chimeric D1-like receptors are shown in left and r
S.E. as obtained by ALLFIT. *P < 0:05 when compared with D1R; #P < 0
IL4B. (C) Constitutive activity of D5R, D1R-IL4B and D5R-IL4A relativ
conditions leading to low receptor expression (as described in A) and high (m
For the low receptor expression condition, intracellular cAMP levels meas
increasing concentrations of DA were expressed relative to D1R basal and i
best-ﬁtted value for relative constitutive activity of D5R and chimeric rece
tivation of AC activity were determined in single wells of a 6-well dish using w
arithmetic meansS.E. of three (high) to four (low) experiments done in
ANOVA with Newman–Keuls post test. For the low receptor expression, the
Bmax values in picomole/mg of membrane proteins (expressed as the arithm
(D1R-IL4B), and 10.1 1.2 (D5R-IL4A). *P < 0:05 when compared with hi
type and chimeric D1-like receptors was assessed under low and high recepto
maximal activation was obtained from dose-response curves analyzed indi
activation of AC was assessed using single wells of a 6-well dish in the prese
three (high) to four (low) experiments done in triplicate determinations. Stat
Keuls post test. The Bmax values for the low and high receptor expression we
expression. (E) The percentage of DA-mediated maximal activation obtaine
basal activity was calculated to normalize dose-response curves shown in A.
ALLFIT as described in Section 2. Statistical signiﬁcance was determined
values approximate S.E. as obtained by ALLFIT are as follows (in nM): 7.
(D5R-IL4A). (F) EC50 ratios of D5R and chimeric receptors relative to the
when compared with D5R.
b4. Discussion
In the study reported here, we have narrowed down the CT
structural determinant responsible for D1-like subtype-speciﬁc
functional properties to the N-terminal segment of CT (Fig. 1),
a region also known as IL4 or H8 in rhodopsin [11,13]. Our
results suggest that variant residues found within IL4 region of
D1-like receptors contribute to the more and less constrained
DA binding conformation displayed by D1R and D5R, re-
spectively. However, our DA binding data with D5R-IL4A fall
short of the results obtained with a chimeric D5R harboring
the entire CT of D1R, which exhibited a full switch in DA
aﬃnity [3,4]. Thus, the spatial relationships induced by IL4 on
D1R and D5R are not reciprocally conferred to the chimeric
receptors, suggesting that IL4 sequence of D1R is not the sole
CT structural determinant involved in regulating DA aﬃnity
at the D1R. There are several lines of evidence supporting this
assertion. Previously, we have reported that a truncated form
of the D1R ending with the IL4 region displayed an increased
DA aﬃnity, suggesting that sequences downstream of the IL4
partake in the formation of a more constrained D1R [5].
Likewise, the third extracellular loop of D1R can impart on its
own a more constrained conformation to the D5R, an eﬀect
that is exacerbated by swapping the entire CT sequences with
those coding for the D1R [18,25]. Alternatively, the CT resi-
dues of D5R left in the D5R-IL4A chimera may interfere with
the constraining eﬀects exerted by IL4 structural determinants
of D1R.
Another aspect of our study is the lack of an aﬃnity switch
of inverse agonists upon IL4 exchange. These results mirror
ﬁndings obtained upon the swap of the entire CT and support
the notion that the subtype-speciﬁc inverse agonist bindingf wild-type and chimeric D1-like receptors expressed in HEK293 cells.
rs using the following amounts of DNA per dish: 0.02 lg of D1R, and
alues in picomole/mg of membrane protein (expressed as the arithmetic
nd 1.3 0.2 (D5R-IL4A). Intracellular cAMP levels were measured in
ations of DA as described under Section 2 and plotted as a function of
experiments done in triplicate determinations and expressed as [3H]-
00. (B) Averaged curves (shown in A) were analyzed by simultaneous
unconstrained and constrained (shared) parameters. The results for
ediated maximal activation of AC (best-ﬁtted parameters for maximal
ight panels, respectively. Results are expressed as values approximate
:05 when compared with D5R; wP < 0:05 when compared with D1R-
e to D1R (set as 1, broken line) was determined under transfection
aximal) receptor expression (using 5 lg of receptor DNA construct).
ured in single wells of a 12-well dish in the absence or presence of
ndividual dose-response curves analyzed using ALLFIT to obtain the
ptors. For the high receptor condition, constitutive and maximal ac-
hole cell cAMP assays in the absence of DA. Results are expressed as
triplicate determinations. Statistical analysis was done using one-way
Bmax values were as stated in A. For the high receptor expression, the
etic meanS.E.) were 12.6 2.1 (D1R), 13.6 0.3 (D5R), 0.6 0.2
gh receptor expression. (D) DA-mediated maximal activation of wild-
r expression. For the low receptor expression condition, DA-mediated
vidually using ALLFIT. For the high receptor expression, maximal
nce of 10 lM DA. Results are expressed as arithmetic meansS.E. of
istical analysis was performed using one-way ANOVA with Newman–
re as stated in A and C. *P < 0:05 when compared with high receptor
d with respective wild-type or chimeric receptor after subtracting the
Normalized curves were analyzed by simultaneous curve-ﬁtting using
using unconstrained and constrained (shared) parameters. The EC50
6 1.1 (D1R), 1.2 0.2 (D5R), 19.6 2.8 (D1R-IL4B), and 22.3 3.2
D1R (broken line). *P < 0:05 when compared with D1R; #P < 0:05
466 K. Tumova et al. / FEBS Letters 576 (2004) 461–467proﬁle is most likely independent of CT-induced conforma-
tional changes [3]. Meanwhile, the increased inverse agonist
aﬃnity observed at both chimeric receptors suggests a poten-
tial role of IL4 region in regulating high aﬃnity binding of this
pharmacological class of dopaminergic ligands.
The functional characterization of our chimeras suggests
that agonist-independent and dependent G protein coupling
properties of the D1-like receptors are diﬀerentially regulated
by IL4. Our studies demonstrated a reversal of agonist-inde-
pendent activation of AC upon a swap of IL4 between D1R
and D5R implying a role of this cytoplasmic region in the
regulation of the thermodynamic equilibrium between active
and inactive conformations of D1-like receptors. A recent
study has implicated IL4 (referred therein as H8) in regulating
the conformational change of leukotriene B4 receptor to the
low aﬃnity state following G protein activation [26]. Fur-
thermore, critical conformational changes of IL4 regulating
potentially the transition between inactive and active states of
rhodopsin have recently been demonstrated [27]. In fact, IL4
has been proposed to function as a conformational switch
alternating between a helical conformation (inactive state) and
a looplike structure (active state) in response to changes in
membrane environment [27]. Likewise, a similar concept of a
helix to coil transition has been put forward as a possible
molecular mechanism underlying G protein coupling of
angiotensin II AT1A receptors [28]. Whether a similar role is
performed by the IL4 of D1R and D5R remains to be inves-
tigated further.
Additionally, IL4 appears to exert a distinct inﬂuence on the
formation of D1-like receptor active states upon DA binding.
In agreement with our previous study highlighting the chimeric
substitution of the full CT, the exchange of IL4 between D1R
and D5R produced a loss of DA potency in both chimeras.
The decrease in DA potency is particularly intriguing for D1R-
IL4B, in light of its increased DA binding aﬃnity. However,
we have recently shown that the third extracellular loop is
required for the CT-induced full switch in DA potency [3,5,18].
Likewise, the third extracellular loop may also act in concert
speciﬁcally with IL4 to impart the subtype-speciﬁc DA potency
to D1-like receptors. Notwithstanding the potential molecular
interplay between the third extracellular loop and IL4, similar
uncoupling of DA aﬃnity and potency has been observed in
our earlier studies and suggests the formation of multiple ac-
tive D1-like conformational states [3,5,18].
New evidence from rhodopsin studies [29,30] also suggests
that diﬀerences in the primary structure of IL4 of D1R and
D5R may underlie some of the subtype-speciﬁc G protein
coupling properties of D1-like receptors. In rhodopsin, IL4 has
been implicated in binding of G protein a and c subunits
[29,30], and thus D1-like receptors may use IL4 to bind to
distinct G protein subunits. In agreement with this view, a
diﬀerential dependence of D1R and D5R on the G protein c
subunit for activation of AC has been shown [31]. Alterna-
tively, post-translational modiﬁcations may also play an im-
portant role in controlling the responsiveness of wild-type and
chimeric D1-like receptors under study. Indeed, palmitoylation
of Cys and PKA phosphorylation taking place in or around
the H8 region have been shown to regulate GPCR desensiti-
zation [6,32–34]. Moreover, IL4-dependent mechanisms may
also be important in regulating Bmax values, thus inﬂuencing
receptor responsiveness. In our study, D1R-IL4B displays a
drastically reduced Bmax, a ﬁnding in line with a similar ob-servation in cells expressing a chimeric D1R harboring the
entire CT of D5R [3,18]. Our preliminary studies show that
D1R and D5R are exclusively expressed at the plasma mem-
brane, while D1R-IL4B is detected at the cell surface and in-
tracellularly (Zhang and Tiberi, data not shown). Intracellular
localization of D1R-IL4B may point toward an increased ER
retention and/or sorting to degradation pathways leading to
Bmax reduction. Additionally, increased agonist-independent
activity of D1R-IL4B may promote its structural instability,
constitutive desensitization and internalization as seen with
other GPCRs [35–38]. Since our G protein coupling studies
were done at similar Bmax values for wild-type and chimeric
receptors, it remains to be clearly established if under our ex-
perimental conditions these cellular processes contribute sig-
niﬁcantly to D1R-IL4B signaling properties (e.g., we may
underestimate the extent of G protein coupling in the absence
of agonist).
Taken together, the results of our study suggest an impor-
tant contribution of IL4 in conferring the distinct DA binding
and G protein coupling properties to D1-like receptors. Al-
though initial reports regarding the role of IL4 in GPCR
function were contradictory [7,39–41], several studies now
suggest that this cytoplasmic region is important for GPCR
binding to and activation of heterotrimeric G proteins
[9,10,26,29,30,42–44]. Our study now shows for the ﬁrst time
that diﬀerences in the primary structure of IL4 may underlie
the structural basis for subtype-speciﬁc ligand binding and G
protein-coupling properties of highly homologous members
belonging to a seven-transmembrane receptor subfamily.
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